COVID 19-Caregivers IGg Seroconversion

• Conditions: Infection, COVID-19
• Interventions: Other: Blood sampling

• Registration Number: NCT04353323
• Lead Sponsor: University Hospital, Limoges

Brief Summary

According to recent publications, the percentage of caregivers infected with COVID 19 is evaluated between 10 and 30% . This great variability is due, on the one hand to the intensity of the influx of covid plus patients and, on the other hand, to the disparity in the preparation of caregivers in the face of this emergency. Indeed, we can understand that the strict application of hygiene rules can be faulted in the face of the volume of patients, the lack of protective equipment and the lack of specific training for caregivers in this area. As a result, within healthcare teams, there are many questions that generate anxiety: will I be able to provide care properly while protecting myself from the risk of contamination? This anxiety is also present and sometimes manifests itself aggressively in the entourage or in the vicinity of caregivers, due to lack of scientific data adapted to the local ecology of the crisis.

Thus, the aim of this study is to show that the risk for caregivers of being contaminated by COVID in an area dedicated to COVID positive patients is no higher than being a caregiver in a non-COVID area that he either in the adult or pediatric sector.

Detailed Description

Not available

Study Timeline

• Status Verified: 2020-04
• Study First Submitted: 2020-04-15
• Study First Submitted QC: 2020-04-17
• Study First Posted: 2020-04-20
• Last Update Submitted: 2020-05-08
• Last Update Posted: 2020-05-11
• Study Start: 2020-05-25
• Primary Completion: 2020-06-25
• Study Completion: 2020-12-25

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 130

Inclusion Criteria

• caregivers staff assigned to a non-intensive care COVID service
• or caregivers staff assigned to a non-COVID adult service
• or caregivers staff assigned to a non-COVID pediatric service
• Age > = 18 years old
• With health insurance
• Express consent

Exclusion Criteria

• Protected persons
• Refusal to participate

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Covid area	Blood sampling	-
Non-Covid area	Blood sampling	-

Primary Outcome Measures

Name	Time	Method
Seroconversion	Day 30	Participants seroconverion will be assessed by analysing IgG When the seroconverion is confirmed (whenever it occurs), the participant ends his partipation.

Trial Locations

Locations (1)

CHU de Limoges; 🇫🇷 Limoges, France